FULL MARKET ACCESS

Integrated Evidence Packages

One coherent evidence base. Every market. Launch-ready.

MARKETS
Core global model adaptable to any market — typically built for UK, Germany, France, and US as a standard package, with further markets added as required.
THERAPY AREAS
All therapy areas — particularly suited to rare disease, oncology, and first-in-class therapies entering multiple markets simultaneously

An Integrated Evidence Package combines multiple model types into a single, coherent market access evidence base. Built around a core global framework with local adaptations, it gives your team everything needed for payer conversations, HTA submissions, and launch strategy across multiple markets.

Is this the right model for you?

What's included

Epidemiological model
eligible patient population sized across target markets
Cost of Illness model
disease burden evidence to frame the unmet need
Budget Impact Model
payer-facing financial impact for each target market
Cost-Effectiveness Model
HTA-ready economic evaluation for each submission
Connecting narrative
a single evidence story that links all models coherently
Local adaptations
each model adapted to local data, costs, and HTA requirements
Full documentation package
technical reports, model files, and HTA-ready summaries

Fee tiers

TIER
FEE
TIMELINE
Launch Readiness
Epi model + COI + BIM, single market
 
£28,000–45,000
10–14 weeks
HTA Ready
Epi model + resource use + CEM, single market
 
£45,000–75,000
14–20 weeks
Global Market Access
Full suite — Epi + COI + BIM + CEM, core global + 3 adaptations
 
£95,000–160,000
20–28 weeks

All fees are fixed price. Scope, deliverables, and timeline are agreed before work begins. Additional market adaptations available — contact us for a tailored quote.

Ready to discuss your project?

Tell us about your indication, your markets, and your timeline.
We'll come back to you within one working day.

BOOK A SCOPING CALL